Valneva (NASDAQ:VALN) Earns “Buy” Rating from HC Wainwright

Valneva (NASDAQ:VALN)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $17.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 134.48% from the stock’s previous close.

Valneva Price Performance

Shares of NASDAQ:VALN opened at $7.25 on Friday. Valneva has a 12 month low of $3.62 and a 12 month high of $9.50. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. The stock’s 50 day moving average price is $6.29 and its 200 day moving average price is $5.61. The stock has a market cap of $589.14 million, a price-to-earnings ratio of -55.77 and a beta of 1.93.

Valneva (NASDAQ:VALN) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.32). Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. Equities research analysts anticipate that Valneva will post 0.13 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Valneva

An institutional investor recently bought a new position in Valneva stock. ABC Arbitrage SA purchased a new stake in Valneva SE (NASDAQ:VALN) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 19,244 shares of the company’s stock, valued at approximately $84,000. 11.39% of the stock is currently owned by institutional investors and hedge funds.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.